Sanofi (SNYNF) Income from Non-Controlling Interests (2009 - 2026)
Sanofi (SNYNF) posted Income from Non-Controlling Interests of $7.0 million for Q1 2026, up 133.53% sequentially from -$21.0 million in Q4 2025, and down 68.2% YoY from $22.1 million in Q1 2025.
Sanofi (SNYNF) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Income from Non-Controlling Interests data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 68.2% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.8 million (down 62.23% YoY) and the FY2025 annual result came in at $44.2 million, down 28.63% from the prior year.
- Income from Non-Controlling Interests grew to $7.0 million in Q1 2026 per SNYNF's latest filing, from -$21.0 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $115.3 million in Q4 2022, with the low at -$82.2 million in Q2 2022.
- Average Income from Non-Controlling Interests over 5 years is $11.5 million, with a median of $12.8 million recorded in 2024.
- The widest YoY moves for Income from Non-Controlling Interests: up 907.79% in 2022, down 952.83% in 2022.
- Sanofi's Income from Non-Controlling Interests stood at $115.3 million in 2022, then tumbled by 102.8% to -$3.2 million in 2023, then jumped by 497.27% to $12.8 million in 2024, then plunged by 263.4% to -$21.0 million in 2025, then soared by 133.53% to $7.0 million in 2026.
- Business Quant data shows SNYNF's Income from Non-Controlling Interests at $7.0 million in Q1 2026, -$21.0 million in Q4 2025, and $36.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.02 Mn |
| Dec 31, 2025 | 39.58 Mn |
| Sep 30, 2025 | 36.24 Mn |
| Jun 30, 2025 | -54.33 Mn |
| Mar 31, 2025 | 22.09 Mn |
| Dec 31, 2024 | 12.82 Mn |
| Sep 30, 2024 | 31.85 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 14.12 Mn |
| Dec 31, 2023 | -3.23 Mn |
| Sep 30, 2023 | 14.15 Mn |
| Jun 30, 2023 | -68.60 Mn |
| Mar 31, 2023 | 15.03 Mn |
| Dec 31, 2022 | 58.15 Mn |
| Sep 30, 2022 | 3.02 Mn |
| Jun 30, 2022 | -82.16 Mn |
| Mar 31, 2022 | 8.98 Mn |
| Dec 31, 2021 | 11.44 Mn |
| Sep 30, 2021 | 30.66 Mn |
| Jun 30, 2021 | 9.63 Mn |